174 related articles for article (PubMed ID: 21932426)
21. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
22. Cabazitaxel for the treatment of prostate cancer.
Michielsen DP; Braeckman JG; Denis L
Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
[TBL] [Abstract][Full Text] [Related]
23. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
[TBL] [Abstract][Full Text] [Related]
24. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K
Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
[TBL] [Abstract][Full Text] [Related]
26. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Caffo O; Pappagallo G; Brugnara S; Caldara A; di Pasquale MC; Ferro A; Frisinghelli M; Murgia V; Russo LM; Soini B; Valduga F; Veccia A; Galligioni E
Urology; 2012 Mar; 79(3):644-9. PubMed ID: 22386418
[TBL] [Abstract][Full Text] [Related]
27. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Amato RJ; Saxena S; Stepankiw M
Cancer Invest; 2013 Mar; 31(3):177-82. PubMed ID: 23402284
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.
Caffo O; Fratino L; Barbieri R; Perin A; Martini T; Sava T; Segati R; Vaccher E; Bernardo Bassan F; Veccia A; Pappagallo G; Galligioni E
Urol Oncol; 2013 Feb; 31(2):180-6. PubMed ID: 21803618
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
[TBL] [Abstract][Full Text] [Related]
31. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P; Zwiebel JA; Moore MJ
Cancer Chemother Pharmacol; 2011 Apr; 67(4):927-33. PubMed ID: 20602233
[TBL] [Abstract][Full Text] [Related]
33. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
Chadha MK; Ashraf U; Lawrence D; Tian L; Levine E; Silliman C; Escott P; Payne V; Trump DL
Prostate; 2008 Sep; 68(13):1461-6. PubMed ID: 18618738
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Ito M; Saito K; Yasuda Y; Sukegawa G; Kubo Y; Numao N; Kitsukawa S; Urakami S; Yuasa T; Yamamoto S; Yonese J; Fukui I
Urology; 2011 Nov; 78(5):1131-5. PubMed ID: 22054387
[TBL] [Abstract][Full Text] [Related]
36. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K; Sugawara S; Saijo Y; Maemondo M; Sato A; Takamori S; Harada T; Sasada T; Kakuma T; Kishimoto J; Yamada A; Noguchi M; Itoh K; Nakanishi Y
J Immunol Res; 2016; 2016():1745108. PubMed ID: 27274999
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
Meulenbeld HJ; Bleuse JP; Vinci EM; Raymond E; Vitali G; Santoro A; Dogliotti L; Berardi R; Cappuzzo F; Tagawa ST; Sternberg CN; Jannuzzo MG; Mariani M; Petroccione A; de Wit R
BJU Int; 2013 Jan; 111(1):44-52. PubMed ID: 22928785
[TBL] [Abstract][Full Text] [Related]
38. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
Arsov C; Winter C; Rabenalt R; Albers P
Urol Oncol; 2012; 30(6):762-71. PubMed ID: 20884252
[TBL] [Abstract][Full Text] [Related]
39. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
40. [Personalized peptide vaccination].
Itoh K; Takahashi R; Yoshitomi M; Terasaki M; Noguchi M
Nihon Rinsho; 2012 Dec; 70(12):2118-23. PubMed ID: 23259383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
